SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular dise ...

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Moderna investors who were adversely affected by alleged securities fraud between January 18, 2023 and June 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moderna-lawsuit-submission-form ...

Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle. However, where sell0offs occur, so too do steep discounts for better value buys. Moreover, while last Monday's sell-off hinted at a potentially volatile market moving forward, American markets recovered quickly, w ...

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securi ...

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 8, 2024. SO WHAT: If you purchased Moderna securities during the Class Peri ...

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Moderna Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the federal securiti ...

LOS ANGELES, Aug. 12, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are e ...

This biotech company's promising pipeline could result in multibillion-dollar revenue. "Buy when there's blood in the streets," was something famous banker Baron Rothschild once advised, suggesting the time to invest is when everyone else is fleeing a particular asset or the market in general. And superstar investor Cathie Wood did just that last week when she added to her holding of Moderna (MRNA -8.06%), buying shares for both her flagship Ark Innovation fund and her Ark Genomic Revolution fund. Moderna s ...

LOS ANGELES, Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Moderna issued a press release on May 31, 2024, disclosing that "the U.S. Food and D ...

COVID-19 vaccine maker Moderna, Inc. MRNA fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe. What Happened: Moderna stock plunged 21.01% to $94.17 on Thursday and fell an incremental 1.73% to $92.54 in premarket trading on Friday, according to Benzinga Pro data. Cathie Wood's Ark Invest capitalized on the weakness and piled into the stock. On Thursday two of Ark's ...